DFX Intelligence

Data Factory

Encelto

ENCELTO is the first and only FDA-approved treatment for adults with idiopathic macular telangiectasia type 2 (MacTel). Please see Important Safety Information, full Prescribing Information, and Patient Information on website.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:3cd7fe91-a756-41f9-b72d-c620625f04ed

Data as of Sep 18, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 20, 2026, 7:30 AM UTC and rebuilt at most every 15 minutes.

Relationships: 1
Dated events: 0
On other graphs: 1
Observed: Sep 16, 2026 to Sep 18, 2026
4 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Private Equityidentity

Encelto

Portfolio company · cited

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Rounds: 0
Investors: 1
People: 0
Website: encelto.com

Investors

Investor	Class	Fund	Partner	Role	Attribution
Omega Fund Management, LLC	Institutional VC	n/a	n/a	unknown	Unknown

Relationships

Invested in (1)

← Omega Fund Management, LLCFirmPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site

Dated events

No dated event names this entity yet.

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:3cd7fe91-a756-41f9-b72d-c620625f04ed
First observed: Sep 16, 2026
Last observed: Sep 18, 2026 46 h ago
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.